OKYO Pharma Files 6-K Report
Ticker: OKYO · Form: 6-K · Filed: 2026-04-07T07:00:07-04:00
Sentiment: neutral
Topics: sec-filing, foreign-issuer, routine-report
TL;DR
OKYO Pharma dropped a 6-K filing on 4/7/26. London HQ.
AI Summary
OKYO Pharma Ltd filed a Form 6-K on April 7, 2026, reporting information as a foreign issuer. The filing includes the 6-K form itself, an exhibit EX-99.1, and a graphic file. The company's mailing and business address is listed as 55 Park Lane, London, UK.
Why It Matters
This filing provides routine updates from OKYO Pharma Ltd, a foreign issuer, to the SEC, offering transparency on its corporate activities.
Risk Assessment
Risk Level: low — This is a routine foreign issuer filing (6-K) and does not appear to contain material financial or operational news.
Key Players & Entities
- OKYO Pharma Ltd (company) — Filer
- 0001849296 (company) — CIK number for OKYO Pharma Ltd
- 2026-04-07 (date) — Filing Date and Period of Report
- 55 PARK LANE LONDON X0 W1K 1NA (location) — Mailing and Business Address
FAQ
What type of SEC filing is this?
This is a Form 6-K, which is a Report of foreign issuer.
Who is the filer of this document?
The filer is OKYO Pharma Ltd.
On what date was this filing accepted by the SEC?
The filing was accepted on 2026-04-07.
What is the CIK number associated with OKYO Pharma Ltd?
The CIK number for OKYO Pharma Ltd is 0001849296.
Where is OKYO Pharma Ltd's business address listed?
OKYO Pharma Ltd's business address is listed as 55 PARK LANE LONDON X0 W1K 1NA.
Filing Stats: 358 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2026-04-07 07:00:07
Filing Documents
- form6-k.htm (6-K) — 24KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-26-015411.txt ( ) — 45KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: April 7, 2026 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated April 7, 2026 4